Skip to main content

Table 1 Baseline characteristics of the 122 one-to-one matched study participants

From: Increased augmentation index in patients with Ehlers-Danlos syndrome

  EDS cohort (n = 61) Healthy control cohort (n = 61) p-value
Sex (f / m) 43 / 18 43 / 18
Caucasian, % 100 100
Age, years 39.3 ± 14.6 35.6 ± 11.4 0.13
Height, cm 168.5 (161.0/174.5) 169.0 (162.5/176.5) 0.47
Weight, cm 65.0 (54.0/76.0) 65.0 (58.0/75.5) 0.73
BMI, kg/m2 22.7 (20.4/25.9) 22.9 (20.8/24.7) 0.96
BSA, m2 1.3 (1.1/1.5) 1.3 (1.2/1.5) 0.81
Neck, cm 33 (31/37) 33 (32/37) 0.70
Waist, cm 73 (67/85) 76 (69.0/81.0) 0.87
Blood pressure systolic (office), mmHg 117.4 ± 14.2 112.8 ± 12.8 0.07
Blood pressure diastolic (office), mmHg 80.6 ± 10.8 76.1 ± 11.8 0.03
Pulse, min−1 76.7 (67/84.7) 69.0 (64.0/76.7) 0.025
Alcohol units per week, units 0 (0/1) 0 (0/2) 0.74
Current Smoker, n (%) 15 (25%) 9 (15%) 0.20
Diabetes, n (%) 3 (4.9%) 0 (0%) 0.08
Arterial hypertension, n (%) 10 (16%) 1 (2%) 0.004
Pack years of smoking, n 0 (0/3) 0 (0/1) 0.11
Antihypertensive drugs, n (%) 10 (16%) 1 (2%) 0.004
NSAIDs, n (%) 13 (21%) 2 (3%) 0.002
Lipid lowering drugs, n (%) 0 0
Antiplatelet drugs, n (%) 1 (1.64%) 0 0.32
Antidiabetic drugs, n (%) 0 0
  1. EDS Ehlers-Danlos Syndrome; BMI Body-Mass-Index; BSA body surface area; NSAID non-steroidal anti-inflammatory drugs